|
|
Blood, 15 March 2005, Vol. 105, No. 6, pp. 2519-2526.
Prepublished online as a Blood First Edition Paper on November 30, 2004; DOI 10.1182/blood-2004-05-2023.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor
Petra S. Bachmann,
Rosemary Gorman,
Karen L. MacKenzie,
Louise Lutze-Mann, and
Richard B. Lock
From the Children's Cancer Institute Australia for Medical Research, Sydney, Australia; and the University of New South Wales, Sydney, Australia.
Glucocorticoids are among the most effective agents used in the treatment of childhood acute lymphoblastic leukemia (ALL), and patient response to treatment is an important determinant of long-term outcome. Despite its clinical significance, the molecular basis of glucocorticoid resistance in lymphoid malignancies is still poorly understood. We have recently developed a highly clinically relevant experimental model of childhood ALL, in which primary childhood ALL biopsies were established as xenografts in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice. The in vivo and in vitro responses of a panel of these xenografts to the glucocorticoid, dexamethasone, reflected the outcome of the patients from whom they were derived. In this report we show that glucocorticoid resistance in B-cell precursor (BCP) ALL xenografts was not due to down-regulation of the glucocorticoid receptor (GR) nor to defective ligand binding of the GR. Moreover, dexamethasone-induced GR translocation from the cytoplasm to the nucleus was comparable in all xenografts. However, glucocorticoid resistance was associated with profoundly attenuated induction of the BH3-only proapoptotic protein, Bim, when xenograft cells were exposed to dexamethasone. These results show that dexamethasone resistance in BCP ALL xenografts occurs downstream of ligand-induced nuclear translocation of the GR, but upstream of Bim induction.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. C. Jaramillo, J. B. Frye, J. D. Crapo, M. M. Briehl, and M. E. Tome
Increased Manganese Superoxide Dismutase Expression or Treatment with Manganese Porphyrin Potentiates Dexamethasone-Induced Apoptosis in Lymphoma Cells
Cancer Res.,
July 1, 2009;
69(13):
5450 - 5457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. V. Cox, P. Diamanti, R. S. Evely, P. R. Kearns, and A. Blair
Expression of CD133 on leukemia-initiating cells in childhood ALL
Blood,
April 2, 2009;
113(14):
3287 - 3296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Pottier, W. Yang, M. Assem, J. C. Panetta, D. Pei, S. W. Paugh, C. Cheng, M. L. Den Boer, M. V. Relling, R. Pieters, et al.
The SWI/SNF Chromatin-Remodeling Complex and Glucocorticoid Resistance in Acute Lymphoblastic Leukemia
J Natl Cancer Inst,
December 17, 2008;
100(24):
1792 - 1803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sharma and A. Lichtenstein
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors
Blood,
August 15, 2008;
112(4):
1338 - 1345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Neale, X. Su, C. L. Morton, D. Phelps, R. Gorlick, R. B. Lock, C. P. Reynolds, J. M. Maris, H. S. Friedman, J. Dome, et al.
Molecular Characterization of the Pediatric Preclinical Testing Panel
Clin. Cancer Res.,
July 15, 2008;
14(14):
4572 - 4583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al.
Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer
Cancer Res.,
April 1, 2008;
68(7):
2321 - 2328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
